The year ahead - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The year ahead
Some predictions about what's in store for contract services in 2010.


Pharmaceutical Technology Europe
Volume 22, Issue 1

The long view

Of course, making predictions about the future is a pretty futile business, and it is fortunate that people generally forget about predictions shortly after they are made. In fact, there are many factors that can affect the course of events in the near term and what looks to be a sure thing today can easily go awry tomorrow.

I recently watched an interview of the superstar investor Warren Buffett by the American journalist Charlie Rose. Commenting on the investment environment, Buffett made an observation that made a big impression. He said: "Things are always uncertain in the short term. What really is certain is that the things that worked over time will continue to work over time. So the next day is always uncertain. The next hour is always uncertain. The longer term is pretty darn certain."

As we look into the future of the pharmaceutical services industry, we can be certain about several things: that rising living standards and ageing populations will drive demand for healthcare; that drugs will continue to be a critical and costeffective part of the health care equation; and that discovery and invention will keep the pharmaceutical industry dynamic. Pharmaceutical services companies can be certain that the pharmaceutical industry will continue to offer new opportunities well into the future; their job will be to figure out how to exploit those opportunities.

Jim Miller is President of PharmSource and a member of Pharmaceutical Technology Europe's Editorial Advisory Board.

The author says...

• The factors that created problems in the pharmaceutical services industry in 2009 are expected to be carried into 2010, with new challenges on the horizon.

• Funding will remain uncertain for a large portion (small and mid-sized firms) of contract services clients, whilst the outcome of corporate reorganization within the pharmaceutical companies formed by the recent big mergers also creates uncertainty.

• Contract services companies will face stiffer competition in 2010 from large pharmaceutical firms that have increased their manufacturing capacity through mergers/acquisitions, as well as from each other as a number of service providers seek to expand their service offerings.

• Although the short-term future of contract services is unsettled, the pharmaceutical industry will continue to offer new opportunities for longterm growth.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
17%
Protecting the supply chain
50%
Expedited reviews of drug submissions
0%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology Europe,
Click here